Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effects of Dapagliflozin on Kidney Health in Patients with Chronic Kidney Disease After Kidney Transplantation

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of the medication dapagliflozin on patients who have undergone a kidney transplant and are experiencing Chronic Kidney Disease (CKD). The medication being tested is known as Forxiga 10 mg film-coated tablets. The purpose of the study is to analyze how this medication affects the kidney's structure and blood flow in patients with reduced kidney function one year after their kidney transplant.

Participants in the study will be randomly assigned to receive either the medication or a placebo. The study will observe changes in the kidney's structure, specifically looking at certain cells and markers that indicate inflammation and stress within the kidney tissue. These observations will be made during a routine biopsy, which is a procedure where a small sample of kidney tissue is taken for examination, one year after the kidney transplant.

The study will last for a period of 12 months, during which the effects of dapagliflozin on the kidney will be closely monitored. The goal is to understand whether this medication can help improve kidney health in patients who have received a kidney transplant and are dealing with Chronic Kidney Disease.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient must provide written consent to participate.

    Eligibility criteria include being between 18 and 75 years old, having a stable kidney function 9 months after transplantation, and for females of childbearing potential, using adequate contraceptive precautions and having a negative pregnancy test.

  2. Step 2

    Medication administration

    The patient will be administered Forxiga 10 mg, which contains the active substance dapagliflozin.

    The medication is taken orally in the form of a film-coated tablet.

  3. Step 3

    Monitoring and assessments

    Throughout the study, the patient will undergo regular monitoring to assess the effects of the medication on kidney structure and function.

    This includes evaluating kidney tissue samples for changes in cell structure, inflammation, and oxidative stress markers during the routine one-year follow-up biopsy.

  4. Step 4

    Study duration

    The study is expected to conclude by December 31, 2025.

    The patient will be involved in the study activities until this date, unless otherwise specified by the study protocol.

Who can join the trial?

5 criteria

  • Patients must be between 18 and 75 years old.
  • Patients must have had a kidney transplant and have a stable kidney function, 9 months after the transplant, regardless of whether they have diabetes or not.
  • Women who can have children must use effective birth control methods.
  • Women who can have children or are within two years of menopause must have a negative urine pregnancy test at the screening visit.
  • Patients must provide written consent to participate in the study.

Who cannot join the trial?

4 criteria

  • Patients who do not have Chronic Kidney Disease (CKD) cannot participate. CKD is a condition where the kidneys are damaged and can't filter blood as well as they should.
  • Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
  • Both male and female patients are eligible, so exclusion is not based on gender.
  • Patients who are considered part of a vulnerable population may be excluded. A vulnerable population includes groups who may have limited ability to give informed consent or are at higher risk of harm.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Dapagliflozin is a medication used in this clinical trial to study its effects on kidney structure and function in patients who have received a kidney transplant. The trial aims to see how this medication affects the kidney's cells and tissues, particularly focusing on inflammation and stress markers. Dapagliflozin is typically used to help control blood sugar levels in people with diabetes, but in this study, researchers are exploring its potential benefits for kidney health after transplantation.

What is already known about the treatment

Dapagliflozin – Dapagliflozin is administered orally in tablet form. It is currently being studied for its effects on kidney health, particularly in patients with chronic kidney disease (CKD) following kidney transplantation. The medication is primarily used to manage blood sugar levels in individuals with type 2 diabetes, but it is also being explored for its potential benefits in kidney function. Dapagliflozin works by inhibiting a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2), which helps reduce blood sugar by preventing glucose reabsorption in the kidneys. It belongs to the class of medications known as SGLT2 inhibitors.

Investigated diseases

Chronic Kidney Disease – Chronic Kidney Disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and excess fluids from the blood. This disease progresses through stages, starting with mild damage and potentially advancing to severe kidney failure. As the kidneys become less effective, waste products and fluids can build up in the body, leading to symptoms such as swelling, fatigue, and high blood pressure. Over time, CKD can affect other body systems, including the heart and blood vessels. The progression of CKD can vary among individuals, with some experiencing a slow decline in kidney function, while others may progress more rapidly. Regular monitoring and lifestyle adjustments are often necessary to manage the condition and slow its progression.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-517885-40-00Protocol codeDapa-TxV1.0Estimated enrolment48 patientsSponsorUniversitaetsklinikum Erlangen AöR

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).